

In Silico Implementation of Paradigmatic Evolutionary Principles in Therapy Design: Resistant Cells as Prospective Inhibitors of Non-Efficient Therapies?

B. Brutovsky

Department of Biophysics, Faculty of Science, Jesenna 5,
P. J. Safarik University, Jesenna 5, 04154 Kosice, Slovakia

D. Horvath

Technology and Innovation Park, Center of Interdisciplinary Biosciences,
P. J. Safarik University, Jesenna 5, 04154 Kosice, Slovakia

In here presented what-if analysis we substitute a unified therapy with a ‘therapy species’, which is the population of heterogeneous therapies evolving accordingly to evolutionary principles. Each therapy within the species may be, at any time, either free or in the exclusive complex with one cell. The therapy is allowed to create the complex with another cell only after its current host cell has died, playing the role of a catalyst. Regarding therapeutic context, the fitnesses of the therapies reflect their respective cytotoxicities in a way which conforms to evolutionary causation. Results of the minimalistic *in silico* modeling indicate that the resistant cells could bias the evolution of the therapies towards more toxic ones by inhibiting non-efficient therapies. In this way, not only therapies govern the evolution of different phenotypes, but variable resistances of cells govern the evolution of therapies as well. As the evolutionary causation of cancer drug resistance has been intensively studied for a few decades, we refer to cancer as a special case to illustrate purely theoretical analysis.

I. INTRODUCTION

Up-to-date therapy design relies on detailed knowledge of biochemical machinery of cancer cells, which is rarely complete. Moreover, static manner of the administration of most therapies sharply contrasts with the fact that many properties of cancer cells that contribute to invasion, metastases and resistance likely arise as successful adaptive strategies to survive and proliferate within temporally unstable micro-environmental conditions [1]. It was shown that adaptive therapeutic intervention that reflects temporal and spatial variability of the tumor microenvironment and cellular phenotype may provide substantially longer survival than standard high dose density strategies [2].

Nowadays, an effort to address heterogeneity and variability of cancer cells in the therapy design is apparent [3–5]. Evolutionarily motivated therapies aim to decrease relative fitness of malignant cells instead of trying to kill them directly. In the strategy of benign cell boosters Maley and Forrest proposed to increase intentionally the proliferation rate of benign cells [6]. Therein, the cells that are sensitive to a cytotoxin are boosted, thereby selecting for chemosensitive cells, and then the toxin is applied. Similarly, Chen et al. designed strategy of an ‘evolutionary trap’ which selects from a karyotypically divergent population the subpopulation with predictably drugable karyotypic feature [7]. In the evolutionary double bind strategy to control cancer, Gatenby at al. exploit that the therapy resistance requires costly phenotypic adaptation that reduces fitness of the respective cells [8]. It has been shown recently that proliferation of malignant cells can be decreased by the administration of non (or minimally) cytotoxic ersatz-

droges [9, 10] thereby the cell’s resources are diverted from the proliferation and invasion towards efflux pump activity, which, consequently, lowers the fraction of the cells with developed drug efflux mechanisms in the population [10]. During recent years, directed evolution of oncolytic viruses has been investigated in virotherapy [11]. Instead of detailed knowledge of the molecular aspects of the interaction between the cancer cell and the virus, the approach exploits evolutionary principles such as diversified population of viral candidates which undergo purposefully designed selection steps to direct evolution towards explicitly pre-defined goal. Usefulness of the approach was demonstrated by successful adaptation of RNA virus to cells in which the tumor suppressor gene p53 had been inactivated (a common feature of cancer cells) [12].

We explore very intuitive idea that the efficient way to fight against evolving cancer cells with heterogeneous and variable mechanisms of resistance [16] is the therapy which itself evolves. Evolution is powerful optimization algorithm, able to overcome many static, as well as dynamic, obstacles [13–15]. To exploit the power of evolution, a few conditions must be fulfilled: i) causal relation between the maximized trait and the fitness exists, ii) fitness of the respective candidate solution results *a posteriori* from a ‘real test’ instead of a *a priori* constructed (in a sense, ‘surrogate’) fitness and, iii) the three evolutionary pillars - phenotypic variation, differential fitness and heritability of fitness [17] apply.

Below we present a minimalistic *in silico* implementation of the above idea into the therapy design. A unified therapy is substituted by a ‘therapy species’, which is the population of heterogeneous and variable therapies. The desired quantity of interest which is to be maximized is cytotoxicity of the respective thera-

pies. The fitness of each therapy from the species is obtained *a posteriori* from its interactions with cell(s). We show that the algorithm can, in principle, arrange that more toxic therapies are applied more often than less efficient ones without need of *a priori* prescribed fitness of the therapy.

II. CANCER AS EVOLUTIONARY PROCESS

Since Nowell conceptualized carcinogenesis as evolutionary process [18], evolutionary theory has been accepted as the appropriate conceptual base to get insight into the *modus operandi* of cancer [18–20]. Evolutionary dynamics equips evolving populations of neoplastic cells with adaptive power and it is considered as the main reason why targeted therapy of cancer fails [21], and why the combination therapy, despite often improved therapeutic outcome, is still not the ultimate winner in the fight against cancer [22]. In this section we briefly review important evolutionary-relevant aspects of cancer which motivated below presented model.

Intratumor Heterogeneity. Improved understanding of the molecular machinery of cancer initiation and progression enabled the development of targeted therapies. However, targeting resistant cells at molecular level is complicated by the diversity of the mechanisms of resistance deployed by cancer cells. Even effective therapies fail face to face the wide range of resistance strategies evolved by cancer cells [16, 23, 24]. These can relate to altered activity of specific enzyme systems, blocked apoptosis, developing transport mechanisms providing multidrug resistance, etc. It has been demonstrated that clonal diversity predicts progression to cancer and that accumulation of viable clonal genetic variants constitutes greater threat of progressing to cancer than homogenizing clonal expansion [25]. Presently, intratumor heterogeneity is assumed to be the central obstacle in the therapy design and many papers have reviewed its causes and consequences to therapeutic resistance during the last decades [23, 26–33].

Epigenetic Plasticity. Importantly, intratumor heterogeneity is not bound exclusively to the differences in the DNA sequences of the cells, but to the epigenetic differences as well. It is known for a long time that epigenetic modifications, such as DNA methylation, histone modifications, chromatin remodeling, and small RNA molecules, play causative role in cancer initiation, progression [34–36] and resistance [37]. Regarding advanced cancer, the therapeutic resilience are attributed not only to genetic diversity but to epigenetic plasticity as well [38]. Considering the timescale during which mutations spread in a cell population, non-genetic instability is made responsible for heterogeneity of cancer cell populations [39]. A major difference between the epigenetic and genetic

changes is that the epigenetic changes are reversible and can fluctuate during the cells lifetime. In difference to genetic changes (mutations), epigenetic modifications of the genome are dynamic and responsive to environmental influence. Moreover, some of epigenetic defects are known to induce genetic changes. For example, the epigenetic defects, such as promoter CpG island hypermethylation - associated silencing of DNA repair genes, are known to cause genetic changes, and translocations and mutations can cause epigenetic disruption, which creates mutual dependencies between epigenetic and genetic traits [40].

Variability in phenotypic characteristics of isogenic cells, known as phenotypic plasticity, confers to cellular tissues important properties, such as the ability of cancer cells to escape a targeted therapy by switching to an alternative phenotype [41]. It motivates effort to stimulate (or prevent) specific phenotype switching purposefully as a therapeutic strategy [42, 43].

Consequently, evolutionary formulated cancer models should include both the above levels, genetic and epigenetic. Conceptual model which links the two types of phenotypic variability, corresponding to the fitness landscape and Waddington's epigenetic landscape, respectively, was proposed [39]. Therein, each genome (representing a point in the fitness landscape) provides the epigenetic landscape of unique topology which contains, due to its mathematical complexity, stable areas (attractors) around stable cell types. Intuitively, probability of the transitions between attractors is proportional to the height of the barriers between them. Accordingly to [39], non-occupied attractors are not exposed to selection and, consequently, are not evolutionarily harmonized with the needs of the tissue and stay pathological. If epigenetic landscape, due to genetic mutations or tumor microenvironment, changes, probability of the cell stuck in cancerous attractors may increase.

Distinguishing between the intratumor heterogeneity due to the differences in DNA sequences and that resulting from epigenetic modifications is instructive for the biological insight as well as for the 'physical' realization of an eventual therapy. Nevertheless, as the genetic and epigenetic changes differ primarily in their stabilities and characteristic timescales (both can be formulated probabilistically) and their contributions may be intertwined, the two physical levels, genetic and epigenetic, should not be viewed separately [40]. For instance, if the cell-state dynamics is identified with Markov model, the differences between genetic and epigenetic states are absorbed by the elements of the transition matrix. The question whether epigenetic states are sufficiently stable (i. e. whether probabilities of transitions are low enough) to enable Darwinian evolution of isogenic cells underpinned by purely epigenetic states is open [44].

Cancer-Relevant Scales. As the genome manifests on multiple timescales, its fitness must be related to the specific timescale (a kind of an ‘investment horizon’) as well. At the proximate timescale, such as the cell’s doubling time, the fitness of the genome can relate to its probability to undergo division. At longer timescale, after the genome produced a clone, the fitness of the genome derives from the size of this clone. Obviously, evolutionary success (or failure) of the genome at short timescale does not necessarily correlates with its evolutionary success on longer timescale. To quantify possible outcome of lineage (or clone) evolution in a more quantitative way, Palmer and Feldman introduced two metrics, k -fitness and k -survivability [45]. The former quantifies probability of increase of the size of the respective lineage after k generations, the latter relates to the likelihood that the species will avoid extinction after k generations. Presuming that the cells in different states differ in their growth properties, then for k increasing the k -fitness depends more and more on the probability distribution of the cell states in the clone (here intratumor heterogeneity) than on the molecular aspects of the cell of clonal origin.

Regarding the timescale at which cancer (and the therapy) has effects, the clone seems to be more relevant structure to determine the fitness of the cell of clonal origin. In this way, the genome implicitly remains the relevant selection unit in the evolution of cancer, nevertheless, with the fitness implicitly derived on longer instead of proximate timescale.

Cell State Dynamics. Cell states result from the interplay of the genome, epigenome, transcriptome and proteome. Due to their tendency to be self-stabilizing, there are typically fewer distinct cell states in a tumor than it could be inferred from the degree of genetic, epigenetic and transcriptional heterogeneity and, straightforwardly, genetically distinct cells may be susceptible to treatment with the same drugs [40]. On the other hand, even genetically identical cells can exist in different cell states, owing to epigenetic differences and influence of the microenvironment. Implied by the fact, that the epigenetic landscape of cancer cells is profoundly altered [46], the cell-state dynamics, as mediated by the interplay of replication, genome stability, phenotypic switching, etc., is in cancer cells population modified as well.

Studying the cell-state dynamics of the three phenotypic fractions within the isogenic population of human breast cancer cells it was observed that these stay under fixed genetic and environmental conditions in equilibrium proportions and the individual cells transition from one state to another with constant interconversion rates per unit time [47]. Consequently, the respective cell-state dynamics was identified with Markov process enabling to apply the universal mathematical properties of Markov processes to study some cancer features. For example, within the framework of Markov model of the cell-state dy-

namics, the probabilities of transitions can be expressed by the elements of the transition matrix, not regarding whether genetic or epigenetic.

Adaptivity of intratumor heterogeneity. Presuming that cells in different states differ in their growth properties, the cell-state composition of the clone inevitably affects the size of the clone and becomes evolutionarily important trait at the cancer-relevant timescale. It was shown, that the genome which enable multiple phenotypic states (phenotypic plasticity) is, under specific environmental regime, advantageous [48]. It was observed, that in the case of variable selective pressure, population of organisms evolve mechanisms to tune the phenotypic variability to the variability of the acting selective pressure [49]. In bacteria, the well known risk-diversification strategy evolved in populations when facing changing environment [50–52] is the bet-hedging strategy [53, 54] which increases the long-term survival and growth of an entire lineage instead of conferring an immediate fitness benefit to any one individual [48]. Based on formal similarity of evolving cancer cells population with bacteria, viruses or yeast, it has been recently proposed that the structure of intratumor heterogeneity is evolutionary trait as well, evolving to maximize clonal fitness at cancer-relevant timescale in changing (or uncertain) environment and that its structure corresponds to the bet-hedging strategy [55–58] which has been recently put into therapeutic context [59].

III. MODEL: THERAPY AS EVOLVING CATALYST

Here we construct a conceptual-level model of the therapy which follows evolutionary ‘construction’ paradigm. The terms cells, therapies, etc. receive only symbolic meanings to reflect analogy with their biological counterparts. Conventional unified therapy designed with deep knowledge of biochemical details is substituted by the therapy species, which is the population of heterogeneous therapies evolving accordingly to evolutionary principles. For simplicity, we assume their equal parametric structure; the therapies within the species differ only in the parameter values. Initially random (and heterogeneous) candidate therapies are selected in direct interactions with cells instead of explicit *a priori* construction of, hopefully, working therapy, which would require substantial specific knowledge of the relevant molecular mechanisms and/or explicit mathematical description. In the model, each cell creates perpetual complex with one of available therapies. At the cell death, the exclusively bound therapy is relinquished and can create complex with another newly born cell, playing, in a sense, the role of catalyst. As discussed later, presuming perpetuity (regarding the cell) and exclusivity of the cell-therapy complexes implicitly identifies toxicities of the respective therapies with their reproductive fitness in a way enabling to direct evolution

of the therapies towards more toxic ones.

Despite its simplicity, the model naturally incorporates essential evolutionary principles and causation. The feasibility of the respective algorithmic steps at biochemical and biological levels is not assumed; short discussion about eventual implementation is postponed to the section VII.

Model of the Cell. Each cell is characterized by the genome consisting of L genes, $g_i \in \{R, M, S, D\}$, $i = 1 \dots L$, representing next action of the cell (here $L = 50$), and the cell state $\phi \in \{0, 1\}$ to discriminate between two possible impacts of an instant environment on the cell, sensitive or resistant respectively, see below. The genes correspond to: **(R)eplication:** the copy of the cell is created, unless the lack of resources ('carrying capacity') prevents it, in which case the cell itself dies; if successful, the copy ('child') inherits the parent's genome and state and, conditionally (see action mutation below), undergoes mutation, **(M)utation:** if randomly chosen gene from the cell's genome is 'M', the gene at randomly chosen position is replaced by any other gene from $\{R, M, S, D\}$; the gene 'M' plays the role only after (R)eplication (in the both, parent and child). **(S)witching:** XOR operation is applied to the cell state ($1 \rightarrow 0$, or $0 \rightarrow 1$, respectively), and **(D)ormancy:** no action is done nor interaction with environment is tested.

For example, the proportion of the 'M' gene in the genome determines the genome stability. Similarly, the proportion of 'S' gene expresses the probability of the cell-state switching, hence the cell state dynamics and survival of the cell. The above *ad hoc* choice of the allowed genome-coded actions reflects here-adopted epitomization of pathogenic cells by cancer cells. For example, as avoiding programmed cell death (apoptosis) is one of the hallmarks of cancer [60] no gene for it is assumed in the above set of actions. The cells die due to the lack of resources at replication or due to the therapy. On the other hand, the dormancy and switching are included as they are often referred as possible alternative ways of drug resistance.

Model of the Therapy. The model parameters were chosen *ad hoc* to characterize the therapies by their time variability and selectivity to the respective cell states. In particular, the environmental factors that effect the cells' fate are integrated in an environmental "state" variable $\mathcal{E}(t)$, t being time, chosen to change continuously between 0 and 1 accordingly

$$\mathcal{E}(t) = \frac{1 \pm \sin(t/T)}{2}, \quad (1)$$

T being the period of the environmental change. Regarding the context of our work, which is the study of survivability and evolvability of cell(s) in different environments, we identify the environment with the therapy (and use the latter term since now).

In the model, the resistance is not bound to a static (physical) characteristics of a cell, but it is rather

viewed as the ability of the cell(s) to survive under an instant therapy. Regarding the time variability of the therapy it follows that the cell in the (physically) same state can be resistant in one moment and sensitive in the other. For convenience, the cell in the state ϕ closer to the value $\mathcal{E}(t)$ is assigned with lower probability of death; regarding here assumed therapeutic interpretation, it is viewed as 'resistant', while the cell in the complementary state (farther from the $\mathcal{E}(t)$ value, higher probability of death) is referred as 'sensitive'. To express this quantitatively, the selectivity of the therapy, \mathcal{S} , is introduced by means of a sigmoid criterion

$$\sigma = \frac{1}{1 + e^{\mathcal{S}(\mathcal{E}(t) - \phi - \mathcal{C})}}, \quad (2)$$

where \mathcal{C} expresses the symmetry of the cell states as well as $\mathcal{E}(t)$. The value of σ determines the fate of the cell, applying the rule

$$\text{action} = \begin{cases} \text{cell death, if } \xi > \sigma, \\ \text{random from genome, otherwise} \end{cases}, \quad (3)$$

where ξ denotes a pseudorandom number generated uniformly from (0,1). In words, until cell dies, it is repetitively confronted with the therapy and, if it survives, it undergoes randomly chosen action from its genome.

Simulation Scheme. The population of N cells in the states $\phi_i \in \{0, 1\}$ with the genomes \mathcal{G}_i $i = 1 \dots N$, each consisting of L genes $g_j \in \{R, M, S, D\}$, $j = 1 \dots L$, evolves along with the population of K heterogeneous therapies, $\mathcal{D}_k \equiv \{T_k, \mathcal{S}_k, \mathcal{C}_k\}$, $k = 1 \dots K$, (1-3). The number of cells, N , during simulation varies, with the carrying capacity as the ultimate size restriction. The population of cells starts with the genomes \mathcal{G}_i , $i = 1 \dots N$, each with randomly generated genes $g_j \in \{R, M\}$, $j = 1 \dots L$, and randomly assigned cell states $\phi_i \in \{0, 1\}$, $i = 1 \dots N$. The population of therapies, $\mathcal{D}_k \equiv \{T_k, \mathcal{S}_k, \mathcal{C}_k\}$, $k = 1 \dots K$, starts with randomly chosen T_k and \mathcal{S}_k values (in all simulations, $\mathcal{C}_k = 0.5$, postulating the symmetry of the sigmoid (2)). In contrast to variable size of the population of cells, the size of the population of therapies is kept constant; the therapies neither replicate, nor die. They only 'mutate', see below.

During the consecutive simulation, the cells and therapies follow the model (1-3). At replication, newly born cell inherits its state and genome from its parent, and the both genomes undergo the above described mutation procedure. In addition, the offspring cell creates exclusive perpetual complex with one of the available therapies \mathcal{D}_k , $k = 1 \dots K$, which, at that moment, slightly modifies its respective T_k and/or \mathcal{S}_k parameters (hence, the therapy 'mutates'). In due times, the interactions of the cell and therapy within the cell-therapy complex is recalculated, and, if the cell 'survives', the random gene from the cell's genome applies. When the cell dies, either due to interaction

with the therapy or the lack of resources at the moment of replication, its respective complex decays and the freed therapy can create complex with another newly born cell, playing the role of a catalyst.

IV. CYTOTOXICITY AS THE FITNESS OF THERAPY

Evolutionary theory is based on the three fundamental principles - phenotypic variation, differential fitness and heritability of fitness [17]. These principles equip evolution with the exceptional power. However, the term ‘fitness’ is conceived differently in biology and in optimization. In biology, the term fitness *a posteriori* expresses selection success of an individual in already *realized* process. Regarding that the selection forces have really applied, the result is *by definition* exact, no matter whether one understands the details of the process or not. Contrary to this, in evolutionary optimization, the term fitness plays the role of a recipe which *a priori* prescribes selection success of the respective individual in the *consecutive* process. The explicit construction of the fitness requires satisfactory knowledge of the details of the problem; if the problem is too complicated and/or varying in time, the appropriate definition of the fitness becomes questionable.

Within here investigated therapeutic context, the straightforward candidate for the fitness of therapy is its cytotoxicity. However, respecting evolutionary causation, the relation between toxicity and fitness must be neither *a priori* nor explicitly defined (as it would be in optimization). Instead, evolutionary causation respecting therapeutic approach requires that the number of iterations of the therapy (hence its fitness) emerges as a consequence of its respective properties as evidenced by the number of killed cells. Simply, it should be arranged that more cytotoxic therapies are, on average, applied more often than less efficient ones without explicit knowledge of molecular, biochemical and/or genetic mechanisms of toxicity. In the model, this crucial step is guaranteed by the requirement of perpetuity and exclusivity of the complexes formed by ‘free’ therapies and newly born cells. The therapy is relinquished after the cell-therapy complex is destroyed; the sooner the therapy destroys the cell-therapy complex, the sooner it can interact with a newly born cell again. As in here proposed algorithm the break-up of the complex is conditioned by the cell death, the fitness of the therapy becomes proportional to its cytotoxicity.

The first principle, **phenotypic variation**, is fulfilled when a therapy is designed as the population of heterogeneous ‘single-cell’ therapies (the ‘therapy species’) which differ in their effects (such as toxicity) on the cells they interact with. In here presented model of the therapy, periodicity and selectivity were chosen intuitively and purely for demon-

stration purposes as the parameters with variable effects on the cells; nevertheless in an eventual application much less intuitive parameters of the therapy can be chosen. At the beginning, representative population of random heterogeneous therapies is generated. They should start as non- (or minimally) toxic, so that sufficient number of cells survives. To maintain heterogeneity within the ‘therapy species’ (hence the exploratory power of the evolution of therapies in the environment systematically influenced by evolving cells as well as the therapies themselves), each therapy undergoes, in successive steps, slight random changes (‘mutations’).

Next evolutionary principle, **differential fitness**, requires that different therapies had different numbers of iterations (in analogy with different rate of survival and reproduction) based on their properties. In here presented approach, the fitness of therapy is *a posteriori* reflected by its toxicity. Here chosen periodicity and selectivity of the therapy confer variable effects on the survival of the cells (see Sections III and V) and, consequently differences in the numbers of iterations of the respective therapies (Sect. V).

The third principle, **heritability of fitness**, requires correlation between parent’s and offspring’s contributions to future generations. However, evolutionary principles do not specify mechanism of inheritance, which can be Mendelian, cytoplasmic, or cultural [17]. In our approach the therapies do not replicate physically but any repeated therapy is slightly mutated offspring of some ‘parent’ therapy (see above Section III), therefore the heritability of the fitness is highly probable.

V. RESULTS

Here, the cell state dynamics is represented by the dependence of the ratio N^1/N on the variable $\mathcal{E}(t)$; N^1 and N are the numbers of cells in the state $\phi = 1$ and the total population size, respectively. Due to fundamentally different physical implementation of the model system, with biological time scales and carrying capacity represented by the CPU and memory limits (see Appendix), the numerical values of \mathcal{T} and \mathcal{S} in the figures below lack biological meaning and are used only to illustrate a few typical regimes. Nevertheless, some results, such as the dependence of the cell state dynamics on the relations between respective parameters, could have universal meaning and provide insights into behavior of biological systems.

A. Homogeneous population under unified therapy

To get deeper insight into later presented results of *in silico* investigation of the evolutionary dynamics of the therapies and cells, we have studied a few cases

of cell state dynamics of non-evolving population of cells under a few different unified therapies. Though most of presented features are rather obvious by intuition, for the readers' convenience we point out the most dominant of them.




FIG. 1: Examples of the cell state dynamics of non-evolving populations of isogenic cells which differ by the probability of the cell state switching - no switching, low (2%) and high (22%) switching rate; for each of the populations two kinds of therapies are applied - low and highly selective, respectively, quantified by the values of the parameter $S = 1, 30$ in (2). Moreover, for all cases four unified therapies differing in their respective periods are applied, as quantified by the values of the parameter $T = 400, 100, 40$ and 10 milliseconds in (1). Red and black color correspond to the plus and minus sign in (1), respectively.

More specifically, we have investigated dependence of the cell state dynamics on the three model parameters, the switching probabilities of the cells (expressed as the ratio of the number of the gene for switching and the length of the genome), and the selectivity and variability of a therapy. In this case, the initial population consists of a few thousands non-evolving ‘isogenic’ cells, each of them starting with randomly assigned state $\phi \in \{0, 1\}$. During simulation, the cells inherit their states from parents. Each cell is exposed to the same therapy $\mathcal{D} \equiv \{T, \mathcal{S}, \mathcal{C}\}$ (to make clear that this does not mean the same \mathcal{E} value for the same cells in different times, we use in the paper the term ‘unified therapy’ instead of the term ‘static’ therapy). Fig. 1 shows convergence of the $(N^1/N, \mathcal{E})$ trajectories for a few respective combinations of the above three parameters, the switching probabilities of the cells, and the selectivity and variability of the therapy. In each plot, two cases of $\mathcal{E}(t)$, corresponding to the respective \pm sign in (1) are depicted. The respective dependences

of the population size on the number of periods are shown in Fig. 2.

In case without switching, the population extincts when the period of the therapy is too long ($T = 400ms$, Fig. 2) for survival of the fraction of the cells in ‘sensitive’ state. The probability of extinction increases with higher selectivity of the therapy (as obvious from the respective plots in Fig. 2). On the other hand, in the case of the shortest investigated period, $T = 10ms$, the ability to switch the cell state does not matter, as the $N^1/N \approx 0.5$ ($S = 1.0$, Fig. 1). However, high selectivity ($S = 30.0$, Fig. 1) can homogenize the cell states in the population of finite states even for very short period (see the respective plot in Figs. 1), no switching needed. Between the two limiting values of periods, $T = 400ms$ and $T = 10ms$, respectively, the population does not extinct and converges to one of two values of N^1/N , 1 or 0.




FIG. 2: Dependence of the population size on the period and selectivity of the therapy and the rate of switching of isogenic cells. Obviously, higher selectivity forces the system to follow the fluctuations of $\mathcal{E}(t)$ unless too short period (here, corresponding to the case $T = 10 ms$) makes it impossible.

When switching is allowed, hysteretic behavior of the cell state dynamics emerges with the width of hysteretic loop depending on the selectivity of the therapy (increases the width) and the switching rate (decreasing the width). It is obvious from the plots in Fig. 1 that similar cell state dynamics can be produced alternatively (for example, lower switching rate can be compensated by higher shorter period to get similar cell state dynamics), which indicates dependence of the cell state dynamics on a scaling form constructed between selectivity, period and the rate of switching. We note that the relation between hysteresis and phenotype switching in evolutionary systems has often been observed and studied [61]. It was shown in bacteria that some antibiotics can in-

duce long-lasting changes in their physiology, termed as cellular hysteresis, that influence bactericidal activity of other antibiotics and can be exploit to optimize antibiotic therapy [62]. However, keeping in mind *ad hoc* choice of the model aimed in particular to provide formal fitness landscapes for here investigated purposes, we leave deeper analysis of the specific hysteretic behavior (or ‘memory effects’ caused by the therapy) of the cell state dynamics and, eventually, scaling properties to future research.

B. Evolving population under evolving therapy.

In this case, the population of therapies evolves side by side with the population of cells. Each cell-therapy complex is exposed simultaneously to two counteract-

ing selection pressures. On one hand, the cells are replicators, hence their fitness is proportional to the numbers of their copies. Longer lifetime of the complex is implicitly supported by the evolution of the cell population, enabling more frequent replication. On the other hand, the complexes are under selection pressure due to the evolution of therapies. Higher number of killed cells *a posteriori* proves that the respective therapy has been iterated more often. It implies that the respective therapy has been more toxic, and, at the same time, more fit (being more often iterated, i. e. reproduced). Being “more fit” means that in the proximate future, it will be applied more often. Hence, shorter lifetime of the complex is supported by the evolution of therapies. Despite the two evolutionary processes differ in their respective reproduction mechanisms, the former creating physical copies

(cells) proportionally to the cell quality while the latter repeating the therapies proportionally to their respective efficiency, both satisfy the fundamental principles of evolution [17].

Regarding the time variable t in $\mathcal{E}(t)$ calculated for each cell-therapy complex individually (1), two alternative implementations were tested; firstly, the cell’s individual time (corresponding to the CPU time consumed by the cell’s respective thread, see Appendix) was applied, providing $\mathcal{E}(0) = 0.5$ at the cell’s birth. In the latter case, the physical time t common to all cells was used, meaning that $\mathcal{E}(t) \in (0, 1)$ at the birth of the cell, introducing high uncertainty into the cell state dynamics. The two cases provide different surfaces of the average lifetimes of the cells, under different therapies (left and right sides in Fig. 3).

Average lifetime vs. density of the therapy space




FIG. 3: Dependence of the average lifetimes of the cells on applied therapy specified by the parameters T , S (upper surfaces) vs. density of the therapy search space (bottom surfaces). The surfaces corresponding to the densities are rescaled for demonstration purposes. The left side of the figure shows the case when the time variable t in $\mathcal{E}(t)$ (1) represents cell’s individual time, starting with $t = 0$ for each complex. The right case corresponds to the case when the time t is physical, common to all the complexes. The additional heat maps are depicted below the respective plots. As the density of the therapy space is recorded after the population has converged to isogenic, the respective average lifetimes depend exclusively on the applied therapies. Despite obvious differences in the surfaces of the average lifetimes in the two cases, the universal feature, which is the correlation of the above-average lifetimes (yellow area, left heat map) with sparsely populated areas in the therapy space (violet area, right heat map) and vice versa, is visible. The colors of the heat maps are scaled to sharpen positions of the extrema in the respective surfaces.

For both the above cases of time, dependence of the average lifetimes of the cells on applied therapies, specified by the parameters \mathcal{T} , \mathcal{S} , was investigated. As the density of the therapy space is recorded after the cells population has converged to isogenic, the differences in the cells' lifetimes are attributed exclusively to the applied therapies. Fig. 3 shows that the therapies conferring, on average, longer lifetimes to the respective cells are underrepresented in the therapy species and vice versa. The explanation of the anticorrelation is straightforward. Each cell adopts one of (slightly 'modified') available therapies at its birth. Even in the case of long living cell ('dormant' cell or the cell 'resistant' to its respective therapy), the therapy is not replaced. It might seem (therapeutically) contraproductive, as it contradicts to an intuitive expectation that the resistant cells should be the primary target of therapies, as resisting cell death is one of the hallmarks of cancer cells [60].

The above controversy, however, reflects the evolutionary causation that we have intentionally built into the structure of the model of therapy. The evolutionary principle which gives evolution its power is the reproduction proportional to fitness, here identified with the cytotoxicity of the therapy. Nevertheless, evolution itself does not specify the mechanism of inheritance [17]. As it was discussed above, here the fitness of a therapy corresponds to the number of its iterations (instead of the number of its physical copies). Straightforwardly, the therapeutic effort is to arrange that more fit (toxic) therapies (from the 'therapy species') are applied more often, and vice versa, if the therapy is not efficient, it should be repeated only rarely. The anticorrelation (Fig. 3) implies that the less efficient therapy is, the less often it is used, which is desired result. To sum up, if it is not possible to determine *a priori* which therapy is the best (and to apply it), one should eliminate less fit therapies.

The next studied feature is the evolution of switching. If the cell's individual time is applied in simulations, meaning that $\mathcal{E}(t)$ is, in a sense, 'synchronized' with the age of the cell-therapy complex (representing strong regularity in the space of therapies), the cells do not evolve switching mechanism. On the other hand, if the physical time, common to all cells is used, the offspring is confronted with uncertain value of $\mathcal{E}(t)$, even if it accidentally applies the same therapy as its parent. This uncertainty leads to the evolution of switching mechanisms, which enables the bet hedging regime. The result is consistent with the theory of the evolution in changing environment [63]. Occurrence of switching, despite changing the surface of the average lifetimes and, consequently, providing different optimum genome (comparing the left and right surface plots in Fig. 3), does not break anticorrelation between the average lifetimes of the cells with the same therapy applied and the number of applications of that therapy (hence density of the therapy space), indicating universality of this feature.

VI. DISCUSSION

In here presented scenario, long living cells serve as 'inhibitors' for non (or less) efficient therapies. As the size of the population of therapies is fixed and less efficient therapies stay bound by resistant cells, more efficient therapies become predominantly available for (and adopted by) newly born cells. By this way, the resistant cells could direct the evolution of the 'therapy species' to more efficient therapies. Nevertheless, as the therapies themselves mutate, less dense areas of the therapy space repopulate by diffusion, retaining exploratory power of algorithm in the case of dynamic environment.

Here, it was required that the therapy may be bound by the next cell only after the current cell's death. By this, we have implicitly associated the fitness of the therapy with its cytotoxicity in evolution-consistent way. However, this requirement disregards that many cancers evolve mutidrug resistance by upregulating membrane efflux pump that exports drugs, thereby ensuring the cell's survival. As in this case are therapies pumped out before fully exhibiting their particular properties (such as their respective cytotoxicity), evolution of the therapies becomes questionable as one of the crucial evolutionary principle, differential fitness [17], is significantly suppressed. On the other hand, the efflux pump comes with the energetic cost [64], which makes the cells with the efflux pump less fit than those without it when the therapy is absent (or nontoxic [9, 10]).

In here presented conceptualization, the therapies are heterogeneous, each of them interacting, in succession, with cells which are heterogeneous in their properties, including differences in their sensitivity to different therapies. If a cell pumps out the therapies not regarding their respective toxicities, it wastes resources and becomes less fit. Therefore, we speculate that in reality, the cells can evolve mechanism(s) enabling them to extrude therapies reflecting level of their respective toxicities. If true, more toxic therapies will prevail in the population, just as in here investigated case when the death of the cell was required to reuse its therapy by the next cell. It would mean that toxicity plays, from the evolutionary viewpoint, the role of the fitness of the therapy no matter whether it shortens the cell's lifetime, or redirecting the cell's resources from replication and invasion to building efflux mechanism(s).

At last but not least, in here presented algorithm, each newly born cell creates the complex with the therapy which is, in general, different from the therapy of its parent. It follows, that even if the offspring has inherited resistance against the therapy of its parent, it might still be sensitive to its own, in addition mutated, therapy, which obviously decreases its (as well as its parent's) fitness. This effect might be more pronounced in the case of cells with unlimited replicative potential, which is one of the cancer hallmarks

[65]. This adds more biological flavor to the model, as most chemotherapeutic drugs are designed effectively target fast-dividing cells.

VII. CONCLUSIONS

In the paper, a unified therapy is substituted by a ‘therapy species’, the evolving constant-sized population of heterogeneous therapies, each of them with the fitness resulting *a posteriori* from its interaction with cells. In this way, not only therapies govern the evolution of different phenotypes, but variable resistance of cells governs the evolution of therapies as well. Our *in silico* investigation indicates that the algorithm can identify the most efficient therapies by inhibiting those which are less efficient (as evidenced by their lower ability to kill the host cell). Not being tailored to some specific molecular mechanisms responsible for the respective cancerous features, the approach could, in principle, to cope with intratumor heterogeneity and stay efficient during adaptation of cancer cells to changed therapy. Moreover, being evolved inside particular tumor, the therapies would be *by definition* personalized.

Despite conceptual simplicity of the above approach, we foresee a number of technical difficulties in its eventual therapeutic implementation. The questions follow: What agent could be used as a replication-

deficient ‘therapy species’? Must it be organic at all? How to ‘mutate’ therapies? How to deliver therapy into the cell, and, subsequently, to avoid the efflux pump, etc. Some of the above issues are omnipresent in cancer research and are intensively studied. Important insights could be gained from virotherapy where the evolutionary principles are used to direct evolution towards explicitly pre-defined goal, and the virus-based gene-therapy which uses replication-deficient viruses as vectors.

In his iconoclastic paper [66] Leonard Adleman proposed that computationally hard problems, such as therein presented NP-complete directed Hamiltonian path problem, can be efficiently solved with algorithmic steps realized by standard tools of molecular biology. We hope that here speculated possible benefits of yet conceptual approach could, perhaps, motivate cancer researchers to test its feasibility in a therapeutically relevant way.

ACKNOWLEDGMENTS

This work was supported by the Scientific Grant Agency of the Ministry of Education of Slovak Republic (VEGA) under the grants No. 1/0250/18 and 1/0156/18.

-
- [1] Gillies, R. J., Brown, J. S., Anderson, A. R. A. & Gatenby, R. A. 2018 Eco-evolutionary causes and consequences of temporal changes in intratumoural blood flow *Nat. Rev. Cancer* **18**, 576–585.
 - [2] Gatenby, R. A., Silva, A. S., Gillies, R. J. & Frieden, B. R. 2009 Adaptive therapy *Cancer Res.* **69**, 4894–4903.
 - [3] Amirouchene-Angelozzi, N., Swanton, C. & Bardelli, A. 2017 Tumor evolution as a therapeutic target *Cancer Discov.* **7**, 805–817.
 - [4] Zhang, J., Cunningham, J. J., Brown, J. S. & Gatenby, R. A. 2017 Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer *Nat. Commun.* **8**, art.1816.
 - [5] Korolev, K. S., Xavier, J. B. & Gore, J. 2014 Turning ecology and evolution against cancer *Nat. Rev. Cancer* **14**, 371–380.
 - [6] Maley, C. C., Reid, B. J. & Forrest, S. 2004 Cancer prevention strategies that address the evolutionary dynamics of neoplastic cells: Simulating benign cell boosters and selection for chemosensitivity *Cancer Epidemiol. Biomark. Prev.* **13**, 1375–1384.
 - [7] Chen, G. *et al.* 2015 Targeting the adaptability of heterogeneous aneuploids *Cell* **160**, 771–784.
 - [8] Gatenby, R. A., Brown, J. & Vincent, T. 2009 Lessons from applied ecology: Cancer control using an evolutionary double bind *Cancer Res.* **69**, 7499–7502.
 - [9] Kam, Y. *et al.* 2015 Sweat but no gain: Inhibiting proliferation of multidrug resistant cancer cells with “ersatzdroges” *Int. J. Cancer* **136**, E188–E196.
 - [10] Enriquez-Navas, P. M., Wojtkowiak, J. W. & Gatenby, R. A. 2015 Application of evolutionary principles to cancer therapy *Cancer Res.* **75**, 4675–4680.
 - [11] Sanjuan, R. & Grdzlishvili, V. Z. 2015 Evolution of oncolytic viruses *Curr. Opin. Virol.* **13**, 1–5.
 - [12] Garijo, R., Hernandez-Alonso, P., Rivas, C., Diallo, J. S. & Sanjuan, R. 2014 Experimental evolution of an oncolytic vesicular stomatitis virus with increased selectivity for p53-deficient cells *PLoS ONE* **9**, e102365.
 - [13] Holland, J. H. 1975 *Adaptation in natural and artificial systems* University of Michigan.
 - [14] Branke, J. 2002 *Evolutionary Optimization in Dynamic Environments* Kluwer Academic Publishers.
 - [15] Morrison, R. W. 2004 *Designing Evolutionary Algorithms for Dynamic Environments* Springer.
 - [16] Gottesman, M. M. 2002 Mechanisms of cancer drug resistance *Annu. Rev. Med.* **53**, 615–627.
 - [17] Lewontin, R. C. 1970 The units of selection *Annu. Rev. Ecol. Syst.* **1**, 1–18.
 - [18] Nowell, P. C. 1976 The clonal evolution of tumor cell populations *Science* **194**, 23–28.
 - [19] Merlo, L. M. F., Pepper, J. W., Reid, B. J. & Maley, C. C. 2006 Cancer as an evolutionary and ecological process *Nat. Rev.*

- Cancer* **6**, 924–935.
- [20] Greaves, M. 2007 Darwinian medicine: a case for cancer *Nat. Rev. Cancer* **7**, 213–221.
- [21] Gillies, R. J., Verduzo, D. & Gatenby, R. A. 2012 Evolutionary dynamics of carcinogenesis and why targeted therapy does not work *Nat. Rev. Cancer* **12**, 487–493.
- [22] Bozic, I. *et al.* 2013 Evolutionary dynamics of cancer in response to targeted combination therapy *eLIFE* **2**, e00747.
- [23] Bedard, P. L., Hansen, A. R., Ratain, M. J. & Siu, L. L. 2013 Tumour heterogeneity in the clinic *Nature* **501**, 355–364.
- [24] Gallaher, J. A., Enriquez-Navas, P. M., Luddy, K. A., Gatenby, R. A. & Anderson, A. R. A. 2018 Spatial heterogeneity and evolutionary dynamics modulate time to recurrence in continuous and adaptive cancer therapies *Cancer Res.* **78**, 2127–2139.
- [25] Maley, C. C. *et al.* 2006 Genetic clonal diversity predicts progression to esophageal adenocarcinoma *Nat. Genet.* **38**, 468–473.
- [26] Turner, N. C. & Reis-Filho, J. S. 2012 Genetic heterogeneity and cancer drug resistance *Lancet* **13**, e178–85.
- [27] Saunders, N. A. *et al.* 2012 Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives *EMBO Mol. Med.* **4**, 675–684.
- [28] Marusyk, A. & Polyak, K. 2010 Tumor heterogeneity: Causes and consequences *Biochim. Biophys. Acta* **1805**, 105–117.
- [29] Marusyk, A., Almendro, V. & Polyak, K. 2012 Intra-tumour heterogeneity: a looking glass for cancer? *Nat. Rev. Cancer* **12**, 323–334.
- [30] Marusyk, A. & Polyak, K. 2013 Cancer cell phenotypes, in fifty shades of grey *Science* **339**, 528–529.
- [31] Meacham, C. E. & Morrison, S. J. 2013 Tumour heterogeneity and cancer cell plasticity *Nature* **501**, 328–337.
- [32] Burrell, R. A., McGranahan, N., Bartek, J. & Swanton, C. 2013 The causes and consequences of genetic heterogeneity in cancer evolution *Nature* **501**, 338–345.
- [33] Fisher, R., Pusztai, L. & Swanton, C. 2013 Cancer heterogeneity: implications for targeted therapeutics *Br. J. Cancer* **108**, 479–485.
- [34] Laird, P. W. 2005 Cancer epigenetics *Hum. Mol. Gen.* **14**, R65–R76.
- [35] Bjornsson, H. T., Fallin, M. D. & Feinberg, A. P. 2004 An integrated epigenetic and genetic approach to common human disease *Trends Genet.* **20**, 350–358.
- [36] Easwaran, H., Tsai, H. C. & Baylin, S. B. 2014 Cancer epigenetics: Tumor heterogeneity, plasticity of stem-like states, and drug resistance *Mol. Cell* **54**, 716–727.
- [37] Hölzel, M., Bovier, A. & Tüting, T. 2013 Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? *Nat. Rev. Cancer* **13**, 365–376.
- [38] Greaves, M. 2015 Evolutionary Determinants of Cancer *Cancer Discov.* **5**, 806–820.
- [39] Huang, S. 2013 Genetic and non-genetic instability in tumor progression: link between the fitness landscape and the epigenetic landscape of cancer cells *Cancer Metastasis Rev.* **32**, 423–448.
- [40] Alizadeh, A. A. *et al.* 2015 Toward understanding and exploiting tumor heterogeneity *Nat. Med.* **21**, 846–853.
- [41] Kemper, K., de Goeje, P. L., Peeper, D. S. & van Amerongen, R. 2014 Phenotype switching: Tumor cell plasticity as a resistance mechanism and target for therapy *Cancer Res.* **74**, 5937–5941.
- [42] Saez-Ayala, M. *et al.* 2013 Directed phenotype switching as an effective antimelanoma strategy *Cancer Cell* **24**, 105–119.
- [43] Montenegro, M. F. *et al.* 2015 Targeting the epigenetic machinery of cancer cells *Oncogene* **34**, 135–143.
- [44] Herman, J. J., Spencer, H. G., Donohue, K. & Sultan, S. E. 2014 How stable 'should' epigenetic modifications be? Insights from adaptive plasticity and bet-hedging *Evolution* **68**, 632–643.
- [45] Palmer, M. E. & Feldman, M. W. 2012 Survivability is more fundamental than evolvability *PLoS ONE* **7**, e38025.
- [46] Liu, F., Wang, L., Perna, F. & Nimer, S. D. 2016 Beyond transcription factors: how oncogenic signalling reshapes the epigenetic landscape *Nat. Rev. Cancer* **16**, 359–372.
- [47] Gupta, P. B. *et al.* 2011 Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells *Cell* **146**, 633–644.
- [48] Carja, O. & Plotkin, J. B. 2017 The evolutionary advantage of heritable phenotypic heterogeneity *Sci. Rep.* **7**, 5090.
- [49] Rando, O. J. & Verstrepen, K. J. 2007 Timescales of genetic and epigenetic inheritance *Cell* **128**, 655–668.
- [50] Crean, A. J. & Marshall, D. J. 2009 Coping with environmental uncertainty: dynamic bet hedging as a maternal effect *Phil. Trans. R. Soc. B* **364**, 1087–1096.
- [51] Forbes, S. 2009 Portfolio theory and how parent birds manage investment risk *OIKOS* **118**, 1561–1569.
- [52] Beaumont, H. J. E., Gallie, J., Kost, C., Ferguson, G. C. & Rainey, P. B. 2009 Experimental evolution of bet hedging *Nature* **462**, 90–94.
- [53] de Jong, I., Haccou, P. & Kuipers, O. P. 2011 Bet hedging or not? A guide to proper classification of microbial survival strategies *BioEssays* **33**, 215–223.
- [54] Donaldson-Matasci, M. C., Lachmann, M. & Bergstrom, C. T. 2008 Phenotypic diversity as an adaptation to environmental uncertainty *Evol. Ecol. Res.* **10**, 493–515.
- [55] Chisholm, R. H., Lorenzi, T. & Clairambault, J. 2016 Cell population heterogeneity and evolution towards drug resistance in cancer: Biological and mathematical assessment, theoretical treatment optimisation *Biochim. Biophys. Acta* **1860**, 2627–2645.
- [56] Nichol, D., Robertson-Tessi, M., Jeavons, P. & Anderson, A. R. A. 2016 Stochasticity in the genotype-phenotype map: Implications for the robustness and persistence of bet-hedging *Genetics* **204**, 1523–1539.
- [57] Gravenmier, C. A., Siddique, M. & Gatenby, R. A. 2018 Adaptation to stochastic temporal variations in intratumoral blood flow: The Warburg effect as a bet hedging strategy *Bull. Math. Biol.* **80**, 954–970.
- [58] Thomas, F. *et al.* 2017 Toward an ultimate explanation of intratumor heterogeneity in B. Ujvari, B. Roche & F. Thomas, editors, *Ecology and evolution of cancer* Elsevier.

- [59] Mathis, R. A., Sokol, E. S. & Gupta, P. B. 2017 Cancer cells exhibit clonal diversity in phenotypic plasticity *Open Biol.* **7**, 160283.
- [60] Hanahan, D. & Weinberg, R. A. 2011 Hallmarks of cancer: The next generation *Cell* **144**, 646–674.
- [61] Friedman, G., McCarthy, S. & Rachinskii, D. 2014 Hysteresis can grant fitness in stochastically varying environment *PLoS ONE* **7**, e103241.
- [62] Roemhild, R. *et al.* 2018 Cellular hysteresis as a principle to maximize the efficacy of antibiotic therapy *Proc. Natl. Acad. Sci. USA* **115**, 9767–9772.
- [63] Levins, R. 1968 *Evolution in Changing Environments: Some Theoretical Explorations* Princeton University Press.
- [64] Silva, A. S., Kam, Y., Khin, Z. P., end R. J. Gillies, S. E. M. & Gatenby, R. A. 2012 Evolutionary approaches to prolong progression-free survival in breast cancer *Cancer Res.* **72**, 6362–6370.
- [65] Hanahan, D. & Weinberg, R. A. 2000 The hallmarks of cancer *Cell* **100**, 57–70.
- [66] Adleman, L. M. 1994 Molecular computation of solutions to combinatorial problems *Science* **266**, 1021–1023.
- [67] Kerrisk, M. 2010 *The Linux Programming Interface: A Linux and UNIX System Programming Handbook* No Starch Press, San Francisco, CA, USA 1st edition.

APPENDIX

The program encoding the above model conforms to the POSIX Threads execution scheme with the round-robin time sharing as implemented in the Linux programming interface API [67], enabling to execute the respective ‘cells’ concurrently as separate threads. More important than an eventual CPU gain, accruing from the program parallelism, is the benefit from delegating some of the model’s parameters to the respective system CPU and memory resources. For example, the size of the cell population derives, apart from the cells ‘genomes’ themselves, from the maximum number of concurrently running threads allowed by the system (representing ‘carrying capacity’ of the population), duration of the thread creation (being the counterpart of the cell replication), size of the thread stack, etc. Owing to the implicit substitution of some model parameters by the system parameters, the implementation of the model is more robust, simpler

and enable to concentrate on particular biologically relevant aspects, such as demonstrated by the above results. Obviously, the hardware constraints can be viewed as the counterpart of the constraints implied by biochemistry which are always present in biological experiments.

Our specific hardware restrictions, such as the maximum allowed concurrently running threads in the system, duration of the thread creation (hundreds of nanoseconds) and cancellation processes, etc, enabled us to simulate populations close to maximum size $N \approx 10000$, Fig. 2. In summary, between 10^7 and 10^8 ($\approx 10^4$ per second) cell-therapy complexes could be tested in a 1-hour simulation. The number of therapies in the therapy species during simulations was kept constant ($K = 32768$), reflecting the particular hardware implementation.